BACKGROUND: Gut microbial translocation (MT) is considered a major cause of immune activation (IA) and failure of immune reconstitution in HIV infection. This study investigated the relationship of virus replication, IA, CD4 counts and MT in HIV-infected children. METHODS: Lipopolysaccharide, bacterial 16S ribosomal DNA (16SrDNA) and soluble CD14 (sCD14) levels were determined in prospectively collected, stored plasma samples from the Pediatric AIDS Clinical Trials Group Protocol P338, a 48-week study initiated in 1997 to compare efficacy of dual nucleosides with a ritonavir-containing regimen. Results of MT were correlated with study data for T cell IA, plasma viral load and CD4 counts in 85 HIV-infected children (ages 2-17 years) designated as virologic responders or virologic failures (VF) at week 44 based on a cutoff of 400 HIV RNA copies/mL. RESULTS: Levels of plasma lipopolysaccharide, 16SrDNA and sCD14 were increased in comparison with HIV-uninfected controls and did not decrease at week 44 even in virologic responders. T cell IA was correlated with viral load and sCD14 at entry and with 16SrDNA and sCD14 at week 44 in total patients and in the VF group. Changes in 16SrDNA correlated with changes in IA and negatively with changes in CD4 counts. 16SrDNA was correlated with sCD14 but not with lipopolysaccharide. CONCLUSIONS: MT persists after 44 weeks of antiretroviral therapy in VS and VF patients. In VF, 16SrDNA exhibited relationships to monocyte and T cell IA and CD4 counts but not with viral load, suggesting a dominant role for MT in disease pathogenesis in HIV-infected children.
BACKGROUND: Gut microbial translocation (MT) is considered a major cause of immune activation (IA) and failure of immune reconstitution in HIV infection. This study investigated the relationship of virus replication, IA, CD4 counts and MT in HIV-infectedchildren. METHODS:Lipopolysaccharide, bacterial 16S ribosomal DNA (16SrDNA) and soluble CD14 (sCD14) levels were determined in prospectively collected, stored plasma samples from the Pediatric AIDS Clinical Trials Group Protocol P338, a 48-week study initiated in 1997 to compare efficacy of dual nucleosides with a ritonavir-containing regimen. Results of MT were correlated with study data for T cell IA, plasma viral load and CD4 counts in 85 HIV-infectedchildren (ages 2-17 years) designated as virologic responders or virologic failures (VF) at week 44 based on a cutoff of 400 HIV RNA copies/mL. RESULTS: Levels of plasma lipopolysaccharide, 16SrDNA and sCD14 were increased in comparison with HIV-uninfected controls and did not decrease at week 44 even in virologic responders. T cell IA was correlated with viral load and sCD14 at entry and with 16SrDNA and sCD14 at week 44 in total patients and in the VF group. Changes in 16SrDNA correlated with changes in IA and negatively with changes in CD4 counts. 16SrDNA was correlated with sCD14 but not with lipopolysaccharide. CONCLUSIONS: MT persists after 44 weeks of antiretroviral therapy in VS and VFpatients. In VF, 16SrDNA exhibited relationships to monocyte and T cell IA and CD4 counts but not with viral load, suggesting a dominant role for MT in disease pathogenesis in HIV-infectedchildren.
Authors: S A Nachman; K Stanley; R Yogev; S Pelton; A Wiznia; S Lee; L Mofenson; S Fiscus; M Rathore; E Jimenez; W Borkowsky; J Pitt; M E Smith; B Wells; K McIntosh Journal: JAMA Date: 2000-01-26 Impact factor: 56.272
Authors: Emmanouil Papasavvas; Livio Azzoni; Andrea Foulkes; Avy Violari; Mark F Cotton; Maxwell Pistilli; Griffin Reynolds; Xiangfan Yin; Deborah K Glencross; Wendy S Stevens; James A McIntyre; Luis J Montaner Journal: Pediatr Infect Dis J Date: 2011-10 Impact factor: 2.129
Authors: W Borkowsky; K Stanley; S D Douglas; S Lee; A Wiznia; S Pelton; R Yogev; K McIntosh; S Nachman Journal: J Infect Dis Date: 2000-06-27 Impact factor: 5.226
Authors: Steven G Deeks; Christina M R Kitchen; Lea Liu; Hua Guo; Ron Gascon; Amy B Narváez; Peter Hunt; Jeffrey N Martin; James O Kahn; Jay Levy; Michael S McGrath; Frederick M Hecht Journal: Blood Date: 2004-04-29 Impact factor: 22.113
Authors: Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: Diana V Avila; Scott A Myers; JingWen Zhang; Giorgi Kharebava; Craig J McClain; Hee-Yong Kim; Scott R Whittemore; Leila Gobejishvili; Shirish Barve Journal: Neuropharmacology Date: 2017-08-12 Impact factor: 5.250
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Scott A Myers; Leila Gobejishvili; Sujata Saraswat Ohri; C Garrett Wilson; Kariena R Andres; Amberly S Riegler; Hridgandh Donde; Swati Joshi-Barve; Shirish Barve; Scott R Whittemore Journal: Neurobiol Dis Date: 2018-12-14 Impact factor: 5.996
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Varghese George; Linda Harrison; Margaret Roach; Xiao-Dong Li; Camlin Tierney; Margaret A Fischl; Judith Aberg; Pablo Tebas; David M Asmuth; Richard B Pollard; Catherine Godfrey; Savita Pahwa Journal: J Infect Dis Date: 2017-11-27 Impact factor: 5.226
Authors: Athena P Kourtis; Chris C Ibegbu; Jeffrey Wiener; Caroline C King; Gerald Tegha; Deborah Kamwendo; Jacob Kumwenda; Surinder P Kaur; Valerie Flax; Sascha Ellington; Zebrone Kacheche; Dumbani Kayira; Charles Chasela; Charles van der Horst; Denise J Jamieson Journal: J Infect Dis Date: 2013-05-17 Impact factor: 5.226